biotech

The biotech resurrection continues
The biotech resurrection continues
EP Vantage
biotech
Lexicon Pharmaceuticals
DBV Technologies
Pfizer
Trillium Therapeutics
Flag link:
Acquisitions of Biotech Startups Increased in 2020, With No Signs of Slowing Down
Acquisitions of Biotech Startups Increased in 2020, With No Signs of Slowing Down
BioSpace
M&A
biotech
startups
Flag link:
5 trends in biotech dealmaking to watch in 2021
5 trends in biotech dealmaking to watch in 2021
BioPharma Dive
biotech
Neuroscience
SPAC
Big Pharma
private equity
Flag link:
After a big year, biotech flotations have much to do
After a big year, biotech flotations have much to do
EP Vantage
IPOs
biotech
Flag link:
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
BioSpace
funding
biotech
IconOVir Bio
oncolytic viruses
cancer
oncology
Aro Biotherapeutics
RNA
Flag link:
3 FDA Dates Biotech Investors Should Circle in 2021
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Flag link:
2021 forecast: In spite of COVID-19—and partly because of it—biotech IPOs have a record year
2021 forecast: In spite of COVID-19—and partly because of it—biotech IPOs have a record year
Fierce Biotech
biotech
pandemic
IPOs
COVID-19
Flag link:
3 Biotech Stocks That Could Explode Higher in 2021
3 Biotech Stocks That Could Explode Higher in 2021
Motley Fool
biotech
biotech stocks
clinical trials
FDA
Argenx
Axsome Therapeutics
CRISPR Therapeutics
Flag link:
[video+transcript]Here's Why Biotech Deals Are All the Rage Right Now
[video+transcript]Here's Why Biotech Deals Are All the Rage Right Now
Motley Fool
biotech
M&A
Biogen
SAGE Therapeutics
Eli Lilly
Precision Biosciences
Merck
OncoImmune
Flag link:
Overnight fortunes are being made in biotech these days — and it's both encouraging and more than a little bit scary
Overnight fortunes are being made in biotech these days — and it's both encouraging and more than a little bit scary
Endpoints
Olema
IPOs
biotech
Flag link:
October sees boost for biotech funding
October sees boost for biotech funding
Biopharma Reporter
funding
biotech
Flag link:
Biotech Investors Rolling the Dice with 250% SPAC Surge
Biotech Investors Rolling the Dice with 250% SPAC Surge
BioSpace
biotech
SPAC
Flag link:
Launch of Unprecedented Biotech Data Resource
Launch of Unprecedented Biotech Data Resource
CP Wire
biotech
statistics
revenue
Scopic
data analytics
Flag link:
Launch of Unprecedented Biotech Data Resource
biotech
statistics
revenue
Scopic
data analytics
Flag link:
Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio
Novartis alums Jimenez, Fishman unveil their next act: Aditum Bio
Fierce Biotech
Joe Jimenez
Novartis
Aditum Bio
biotech
funding
Flag link:
Patrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot'
Patrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot'
Endpoints
Patrick Soon-Shiong
NantKwest
cancer moonshot
cancer
biotech
Flag link:
A record number of biotechs are going public. Here's how they're performing.
A record number of biotechs are going public. Here's how they're performing.
BioPharma Dive
IPOs
biotech
Flag link:
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
Endpoints
MD Anderson
biotech
funding
cancer
oncology
Flag link:
Biopharma buyouts still pricey
Biopharma buyouts still pricey
EP Vantage
M&A
biotech
pandemic
COVID-19
Flag link:
The two months in 1980 that shaped the future of biotech
The two months in 1980 that shaped the future of biotech
Stat
Nobel Prizer
biotech
IPOs
DNA
Genenetech
Flag link:

Pages